Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiquimod Gel for Common Warts in Pediatric Subjects
NCT00116675Phase 2Completed
- Sponsor
- Graceway Pharmaceuticals
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of resiquimod in common warts (3 arms), sponsored by Graceway Pharmaceuticals. Primary endpoint: Clearance of treated wart(s). Started Mar 2005; status: completed.
02
Drugs
resiquimod
03
Conditions
common warts
Beyond the preview
Go deeper on NCT00116675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116675.